Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Ross

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
The New England Journal of Medicine|February 19, 2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerSandra M Swain, José Baselga, Sung-Bae Kim, et al.
The Lancet. Oncology|April 23, 2013
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain, Sung-Bae Kim, Javier Cortés, et al.
Clinical Chemistry|August 22, 2025
A Parametric Empirical Bayes Approach to Personalized Reference Intervals and Reference Change ValuesEirik Åsen Røys, Kristin Viste, Christopher-John Farrell, et al.
Clinical Pharmacology and Therapeutics|May 16, 2002
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumorsDiane R Mould, Nicholas H G Holford, Jan H M Schellens, et al.
The New England Journal of Medicine|December 14, 2011
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerJosé Baselga, Javier Cortés, Sung-Bae Kim, et al.
Clinical Biochemistry|October 16, 2022
Oral glucose tolerance test to diagnose gestational diabetes mellitus: Impact of variations in specimen handlingEmma L Jamieson, Goce Dimeski, Robert Flatman, et al.
Anti-Cancer Drugs|August 24, 2013
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxelJavier Cortés, Sandra M Swain, Iveta Kudaba, et al.
The Lancet. Oncology|May 16, 2016
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
The Lancet. Oncology|December 14, 2011
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
The New England Journal of Medicine|February 19, 2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerSandra M Swain, José Baselga, Sung-Bae Kim, et al.
The Lancet. Oncology|April 23, 2013
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain, Sung-Bae Kim, Javier Cortés, et al.
Clinical Chemistry|August 22, 2025
A Parametric Empirical Bayes Approach to Personalized Reference Intervals and Reference Change ValuesEirik Åsen Røys, Kristin Viste, Christopher-John Farrell, et al.
Clinical Pharmacology and Therapeutics|May 16, 2002
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumorsDiane R Mould, Nicholas H G Holford, Jan H M Schellens, et al.
The New England Journal of Medicine|December 14, 2011
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerJosé Baselga, Javier Cortés, Sung-Bae Kim, et al.
Clinical Biochemistry|October 16, 2022
Oral glucose tolerance test to diagnose gestational diabetes mellitus: Impact of variations in specimen handlingEmma L Jamieson, Goce Dimeski, Robert Flatman, et al.
Anti-Cancer Drugs|August 24, 2013
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxelJavier Cortés, Sandra M Swain, Iveta Kudaba, et al.
The Lancet. Oncology|May 16, 2016
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
The Lancet. Oncology|December 14, 2011
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
Pageof 4